FDA Releases Staff Review of Merck Covid-19 Pill
U.S. health regulators are expected to release a staff assessment on Friday about Merck & Co.’s promising Covid-19 pill. and Ridgeback Biotherapeutics LP.
The Food and Drug Administration staff report is expected to include analysis of clinical trial data for the drug molnupiravir, which the companies say reduces the risk of hospitalization and death in people at high risk for severe Covid-19. infections.